- Home
- IMAB
IMAB
I-MAB
as 01-17-2025 4:00pm EST
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 83.8M | IPO Year: | 2020 |
| Target Price: | $8.00 | AVG Volume (30 days): | 673.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.84 - $2.08 | Next Earning Date: | 03-13-2025 |
| Revenue: | $3,313,984 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest I-MAB News
IMAB Breaking Stock News: Dive into IMAB Ticker-Specific Updates for Smart Investing
PR Newswire
10 days ago
I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member
Simply Wall St.
11 days ago
US Penny Stocks To Watch In January 2025
Clinical Trials Arena
11 days ago
I-Mab pauses CD73 antibody development in pipeline reshuffle
MT Newswires
12 days ago
I-Mab to Prioritize Givastomig as Lead Program; Shares Rise
PR Newswire
12 days ago
I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program
Simply Wall St.
a month ago
I-Mab Leads Our Spotlight On 3 US Penny Stocks
PR Newswire
2 months ago
I-Mab to Participate at the Piper Sandler Healthcare Conference
Simply Wall St.
2 months ago
I-Mab Third Quarter 2024 Earnings: US$0.25 loss per share (vs US$0.57 loss in 3Q 2023)
Compare IMAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMAB I-MAB - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.